Literature DB >> 11546608

Effective decision-making: progressing compounds through clinical development.

C A. Shillingford1, C W. Vose.   

Abstract

In today's drug-development environment, companies are under increasing pressure to improve efficiency and maintain returns on investment. Tomorrow's environment is likely to be harsher still, and companies that survive and prosper will be those that are already responding by re-inventing their structures and culture to meet the challenges that lie ahead. In this review, we explore some of the strategies and issues that are central to this process, with particular reference to decision-making in drug development.

Year:  2001        PMID: 11546608     DOI: 10.1016/s1359-6446(01)01945-6

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  3 in total

1.  An exercise programme for community-dwelling, mobility-restricted and chronically ill older adults with structured support by the general practitioner's practice (HOMEfit). From feasibility to evaluation.

Authors:  T Hinrichs; M Brach; C Bucchi; A Moschny; S Wilm; U Thiem; P Platen
Journal:  Z Gerontol Geriatr       Date:  2013-01       Impact factor: 1.281

2.  A call to restructure the drug development process: government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care.

Authors:  Thomas C Jones
Journal:  Sci Eng Ethics       Date:  2005-10       Impact factor: 3.525

3.  From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine.

Authors:  Erfan Younesi; Martin Hofmann-Apitius
Journal:  EPMA J       Date:  2013-11-06       Impact factor: 6.543

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.